Nancy J. Hutson, a director at Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX), recently sold 7,000 shares of the company's common stock, according to a regulatory filing. The shares were sold at a weighted average price of $7.54, yielding a total transaction value of approximately $52,780. The transaction comes as BCRX shows strong momentum with a 25.71% year-to-date return and maintains a solid market capitalization of $1.54 billion. This transaction was part of a pre-established trading plan under Rule 10b5-1, which was adopted to cover tax liabilities from the vesting of restricted stock units. Following the sale, Hutson retains ownership of 86,638 shares in the company. InvestingPro data shows the company maintains strong liquidity with a current ratio of 2.78 and impressive revenue growth of 29.92% over the last twelve months. Discover more insights and detailed analysis in the comprehensive Pro Research Report, available with an InvestingPro subscription.
In other recent news, BioCryst Pharmaceuticals (NASDAQ:BCRX) has reported a substantial 36% year-over-year increase in its third-quarter revenue, primarily driven by its ORLADEYO product, with total revenue reaching $117.1 million. Furthermore, the company has revised its 2024 revenue guidance to a range of $430 to $435 million and projects to achieve $1 billion in annual revenue by 2029.
BioCryst Pharmaceuticals is advancing its clinical trials, with BCX17725 for Netherton syndrome recently entering the clinical stage. The company also plans to submit regulatory filings for an oral prophylactic therapy for children with hereditary angioedema by 2025.
The company reported an operating profit of $24.9 million, excluding stock compensation, and ended the quarter with robust cash reserves of $351.7 million. A slowdown in quarterly sales growth for ORLADEYO is anticipated in Q4 2024 and 2025.
These are recent developments and part of the company's strategic focus on expanding its product market presence and advancing its pipeline while maintaining financial discipline. It's worth noting that the company aims for quarterly cash flow positivity by late 2024 and full-year profitability in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.